Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$14.47 USD
+0.09 (0.63%)
Updated Oct 6, 2025 04:00 PM ET
After-Market: $14.41 -0.06 (-0.41%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADPT 14.47 +0.09(0.63%)
Will ADPT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
Other News for ADPT
Adaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade)
DASH, DE, BABA: Cathie Wood Loads Up on DoorDash, Deere & Alibaba, Trims Stakes in ADPT and Others
ADPT forms Upper Bollinger Band Walk on October 3
Is ADPT poised for gains? Slingshot Bullish shows up after slipping 0.76%
Is ADPT set to rally? New 52 Week High shows up after declining 2.67%